Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Unknown 21Completed 14Recruiting 11Not yet recruiting 5Terminated 4Active not recruiting 4Withdrawn 3Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Endoscopic Mucosal Resection × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

NCT04919824 2026-03-24

Monopolar Current Cutting Knife vs Bipolar RFA Knife

Baylor College of Medicine

Phase NA Active not recruiting
80 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT05078866 2026-03-03

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
45 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡